The well-documented immunomodulatory effect of GSK-J4 in inflammatory conditions suggests that KDM6A/B inhibition could alter the immune microenvironment of solid tumours in favour of an anti-inflammatory, tolerogenic milieu, possibly promoting immune evasion by tumour cells. Here, KDM6A is linked to neoplasm.